
There are no published conclusive phase III controlled clinical trials nor general consensus about treatment approaches despite several years of coordinated efforts in basic and clinical zzso zzso practice guidelines for the prevention and treatment of zzso muscle wasting are zzso The purpose of this review is to supply an update on the promising agents and/or combined approaches for the treatment of cancer zzso 

The choice for cancer zzso treatment in clinical practice is very zzso the only approved drugs in Europe are zzso Several drugs with a strong rationale have failed or have not shown zzso results in clinical zzso they include zzso acid, zzso zzso and zzso necrosis factor zzso zzso zzso Several emerging drugs have shown promising results but are still under clinical investigation zzso selective zzso zzso zzso zzso zzso zzso zzso Moreover, increasing knowledge of zzso zzso and preliminary clinical findings seem to suggest that a combined treatment approach may be the most effective zzso 

A number of promising new agents are currently being developed but are not as yet regarded as standard of zzso They include: selective zzso zzso zzso zzso zzso selective zzso zzso zzso zzso olanzapine, zzso zzso and an innovative approach of zzso combined zzso The data reported seem to suggest that the most effective treatment for cancer zzso may be a combination regimen rather than zzso zzso This is in keeping with the general consensus that cancer zzso is a zzso process and, zzso a potentially effective approach should be zzso 

